A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation

Metastatic breast cancer (MBC) is the most life-threatening disease in women worldwide. HER2-mutated breast carcinoma has been reported to benefit from HER2-targeted tyrosine kinase inhibitors recently. Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Lei, Ye, Wei-Wu, Zheng, Lin-Feng, Huang, Ping, Shi, Lei, Huang, Jian, Zheng, Ya-Bing, Chen, Zhan-Hong, Wang, Xiao-Jia, Wang, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475092/
https://www.ncbi.nlm.nih.gov/pubmed/31118664
http://dx.doi.org/10.2147/OTT.S199931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475092/
https://www.ncbi.nlm.nih.gov/pubmed/31118664
http://dx.doi.org/10.2147/OTT.S199931

Ejemplares similares